The FINANCIAL — Takeda Pharmaceutical Company Limited ("Takeda") on March 23 announced that it has signed an agreement with Wyeth for the product licence for Prostap (leuprorelin acetate), an LH-RH agonist, to transfer back to Takeda from Wyeth in the UK and Republic of Ireland.
This follows the expiry of the agreement between the two companies under which Wyeth has held the marketing authorisation for Prostap (Leuprorelin acetate) from Takeda in the UK and the Republic of Ireland since 1990.
The marketing for Prostap will now revert to Takeda from 1 July 2009. From this date, the entire Prostap product range will be marketed in the UK and Republic of Ireland by Takeda UK Limited, a wholly owned subsidiary of Takeda. Wyeth will continue to hold the marketing authorisation until this time. Both parties are working closely together to ensure a smooth transition process, in particular recognising the key importance of maintaining an uninterrupted supply of Prostap products to all patients and customers.
“The addition of Prostap will enrich our product portfolio, which currently consists of Amias, Actos and Competact and is a logical development of our plan to develop a substantial franchise in the oncology market”, commented Trevor Smith, Takeda UK’s Managing Director.